The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Lipoprotein(a) and Atherosclerosis
Abstract
Lipoprotein(a) [Lp(a)], a lipoprotein variant, was relegated for almost 25 years to the study of a few specialists. During the past 3 to 4 years, however, there has been a tremendous upsurge of interest in Lp(a), primarily because of multidisciplinary efforts in structural and molecular biology. Findings emerging from these efforts include the following: Lp(a) represents a cholesteryl-ester, low-density-lipoprotein (LDL)-like particle with apolipoprotein (apo) B-100 linked to apo(a); apo(a) is a glycoprotein coded by a single gene locus on the long arm of chromosome 6, which has several alleles, accounting for its remarkable size polymorphism (300 to 800 kD); apo(a) size polymorphism relates to plasma levels and density distribution of Lp(a); apo(a) is strikingly similar to plasminogen; and in vitro, Lp(a), in appropriate levels, competes for some physiologic functions of plasminogen in the coagulation and fibrinolytic cascade and may thus be thrombogenic. The LDL-like properties of Lp(a) may also confer atherogenic potential, but the mechanisms underlying this atherogenicity remain to be defined. In epidemiologic studies, high plasma Lp(a) levels have been associated with an increased incidence of atherosclerotic cardiovascular disease, especially in patients less than 60 years of age. Moreover, Lp(a) has been found as an intact particle in the arterial intima, particularly in association with atherosclerotic plaque. This finding suggests that Lp(a) can transverse the endothelium, possibly by a non-receptor-mediated process, and, at the intimal level, acquire thrombogenic and atherogenic potentials. Current information justifies the need to determine plasma Lp(a) levels in patients with a history of atherosclerotic cardiovascular disease. Unfortunately, the available techniques need to be standardized. Apolipoprotein(a) exists in isoforms of different sizes, and the importance of determining apo(a) phenotypes in clinical practice remains to be established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
Self-citationA NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,372
Self-citationThe mysteries of lipoprotein(a).
Utermann, G. (1989) · Science · doi:10.1126/science.2530631 · Cited by 1,257
Dahlen, G. H., Guyton, J. R., Attar, M., Farmer, J. A., Kautz, J. A., & Gotto, A. M. (1986) · Circulation · doi:10.1161/01.cir.74.4.758 · Cited by 911
Utermann, G., Menzel, H. J., Kraft, H. G., Duba, H. C., Kemmler, H. G., & Seitz, C. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113093 · Cited by 881
Lp(a) Lipoprotein as a Risk Factor for Myocardial Infarction
Rhoads, G. G. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03380180102027 · Cited by 783
Hajjar, K. A., Gavishi, D., Breslow, J. L., & Nachman, R. L. (1989) · Nature · doi:10.1038/339303a0 · Cited by 702
Armstrong, V. W., Cremer, P., Eberle, E., Manke, A., Schulze, F., Wieland, H., Kreuzer, H., & Seidel, D. (1986) · Atherosclerosis · doi:10.1016/0021-9150(86)90099-7 · Cited by 626
Seed, M., Hoppichler, F., Reaveley, D., McCarthy, S., Thompson, G. R., Boerwinkle, E., & Utermann, G. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005243222104 · Cited by 585
A potential basis for the thrombotic risks associated with lipoprotein(a)
Miles, L. A., Fless, G. M., Levin, E. G., Scanu, A. M., & Plow, E. F. (1989) · Nature · doi:10.1038/339301a0 · Cited by 583
Self-citation
Cited by
Bhutto, I., & Lutty, G. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.04.005 · Cited by 1,005
Haskell, W. L., Alderman, E. L., Fair, J. M., Maron, D. J., Mackey, S. F., Superko, H. R., Williams, P. T., Johnstone, I. M., Champagne, M. A., & Krauss, R. M. (1994) · Circulation · doi:10.1161/01.cir.89.3.975 · Cited by 884
Haycock, P. C., Burgess, S., Wade, K. H., Bowden, J., Relton, C., & Davey Smith, G. (2016) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.118216 · Cited by 600
A Prospective Study of Lipoprotein(a) and the Risk of Myocardial Infarction
Ridker, P. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510180065035 · Cited by 512
Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein(a)
Grainger, D. J., Kirschenlohr, H. L., Metcalfe, J. C., Weissberg, P. L., Wade, D. P., & Lawn, R. M. (1993) · Science · doi:10.1126/science.8503012 · Cited by 408
Self-citation
Metadata
- Authors
- Scanu, A. M., Lawn, R. M., & Berg, K.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1991-08-01
- Volume
- 115
- Issue
- 3
- Pages
- 209-218
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2029003946
- Cited by
- 276
- References
- 54
- FWCI
- 25.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipoprotein(a) and Atherosclerosis. https://app.cochat.ai/papers/10.7326/0003-4819-115-3-209
- The paper
- Scanu, A. M., Lawn, R. M., & Berg, K. (1991). Lipoprotein(a) and Atherosclerosis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-115-3-209
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.